Pattern and economic impact of cutaneous adverse drug reactions: Initial experiences from the regional pharmacovigilance center, Western Nepal

International Journal of Risk and Safety in Medicine

Volumn 18, Issue 3, 2006, Pages 163-171

  Mishra, P ^a   Subish, P ^a   Gupta, S ^a   Shankar, P R ^b   Bista, D ^b   Chhetri, A K ^b   Bhandari, R B ^a  

^a MANIPAL TEACHING HOSPITAL   (Nepal)

^b MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

Author keywords

Adverse drug reaction reporting systems; Causality assessment; Economic impact

Indexed keywords

ANTHELMINTIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIPARASITIC AGENT; CORTICOSTEROID; DIURETIC AGENT; EMOLLIENT AGENT; HERBACEOUS AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; HORMONE; KERATOLYTIC AGENT; LIQUID PARAFFIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SPASMOLYTIC AGENT; SUNSCREEN; TUBERCULOSTATIC AGENT; VITAMIN;

ADOLESCENT; ADULT; AGED; ALGORITHM; ALOPECIA; ANGIONEUROTIC EDEMA; ARTICLE; CHILD; CONTACT DERMATITIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA ANALYSIS; DISEASE SEVERITY; DRUG ERUPTION; DRUG SURVEILLANCE PROGRAM; ECONOMIC EVALUATION; ERYTHEMA; ERYTHEMA MULTIFORME; FEMALE; FIXED DRUG ERUPTION; HUMAN; MACULOPAPULAR RASH; MALE; MEDICAL RECORD; NEPAL; PAPULE; PAPULOVESICULAR RASH; PITYRIASIS ROSEA; PRURITUS; TREATMENT DURATION; URTICARIA; VASCULITIC RASH;

EID: 33748912490     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. I. Ayani, C. Aguirre, G. Gutierrez, A. Madariaga, J.M. Rodriguez-Sasiain and M.J. Martinez-Bengoechea, A cost analysis of suspected adverse drug reactions in a hospital emergency ward, Pharmacoepidemiol. Drug. Saf. 8 (1999), 529-534.
2. D.W. Bates and L. Leape, Adverse drug reaction, in: Morreli's Clinical Pharmacology, S.G. Carvuthers, B.B. Hoffman, K.L. Melmon and D.W. Nierenberg, eds, McGraw-Hill, Boston, 2000, pp. 1223-1257.
3. D.W. Bates, N. Spell, D.J. Cullen, E. Burdick, N. Laird, L.A. Petersen, S.D. Small, B.J Sweitzer and L.L. Leape, The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group, JAMA 227 (1997), 307-311.
4. K. Blacker, R. Stern and B.U. Wintroub, Cutaneous reactions to drugs, in: Dermatology in General Medicine, T. Fitzpatrick, A. Eisen and K. Wolft, eds, McGraw-Hill, New York, 1993, pp. 1783-1794.
5. D.C. Classen, S.L. Pestotnik, R.S. Evans, J.F. Lloyd and J.P. Burke, Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributable mortality, JAMA 277 (1997), 301-306.
6. R.I. Edwards and J.K. Aronson, Adverse drug reactions: definitions, diagnosis, and management, Lancet 356 (2000), 1255-1259.
7. F. Fiszensin-Albala, V. Auzerie, E. Mahe, R. Farinotti, C. Durand-Stocco, B. Crickx and V. Descamps, A 6-month prospective survey of cutaneous drug reactions in a hospital setting, Br. J. Dermatol. 149 (2003), 1018-1022.
8. K. Gholami and G. Shalviri, Factors associated with preventability, predictability, and severity of adverse drug reactions, Ann. Pharmacother. 33 (1999), 236-240.
9. M. Goettler, S. Schneeweiss and J. Hasford, Adverse drug reaction monitoring - cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission, Pharmacoepidemiol. Drug. Saf. 6(Suppl. 3) (1997), S79-90.
10. S.C. Hartwig, J. Siegel and P.J. Schneider, Preventability and severity assessment in reporting adverse drug reactions, Am. J. Hosp. Pharm. 49 (1992), 2229-2232.
11. E.G. Holland and F.V. Degruy, Drug-induced disorders, Am. Fam. Physician 56 (1997), 7.
12. P. Magee, Drug-induced skin disorders, in: Clinical Pharmacy and Therapeutics, R. Walker and C. Edwards, eds, Churchill Livingstone, Philadelphia, 2003, pp. 843-852.
13. L. Naldi, A. Conforti, M. Venegoni, M.G. Troncon, A. Caputi, E. Ghiotto, A. Cocci, U. Moretti, G. Velo and R. Leone, Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions, Br. J. Clin. Pharmacol. 48 (1999), 839-846.
14. C.A. Naranjo, U. Busto, E.M. Sellers, P. Sandor, I. Ruiz, E.A. Roberts, E. Janecek, C. Domecq and D.J. Greenblatt, A method for estimating the probability of adverse drug reactions, Clin. Pharmacol. Ther. 30 (1981), 239-245.
15. M.V. Noel, S. Sushma and S. Guido, Cutaneous adverse drug reactions in hospitalized patients in a tertiary care center, Indian J. Pharmacol. 36 (2004), 292-295.
16. S. Puavilai and P. Timpatanapong, Prospective study of cutaneous drug reactions, J. Med. Assoc. Thai 72 (1989), 167-171.
17. D. Pudukadan and D.M. Thappa, Adverse cutaneous drug reactions: clinical pattern and causative agents in a tertiary care center in South India, Indian J. Dermatol. Venereol. Leprol. 70 (2004), 20-24.
18. M. Ramesh, J. Pandit and G. Parthasarathi, Adverse drug reactions in a south Indian hospital - their severity and cost involved, Pharmacoepidemiol. Drug. Saf. 12 (2003), 687-692.
19. J.C. Roujeau and R.S. Stern, Severe adverse cutaneous reactions to drugs, N. Engl. J. Med. 331 (1994), 1272-1285.
20. G.T. Schumock and J.P. Thornton, Focusing on the preventability of adverse drug reactions, Hosp. Pharm. 27 (1992), 538.
21. P. Subish, P. Mishra, B.M. Shrestha, P.R. Shankar, D. Bista and B. Purwar, Contribution of the regional drug information center towards drug safety - an experience from western Nepal, in: International Workshop on Adverse Drug Reaction Monitoring & 4th Annual Conference of Society of Pharmacovigilance India, 22-23 January 2005, MJP Rohilkhand University, Bareilly, India.
22. M. Sushma, M.V. Noel, M.C. Ritika, J. James and S. Guido, Cutaneous adverse drug reactions: A 9-year study from a South Indian hospital, Pharmacoepidemiol. Drug. Saf. 14 (2005), 567-570.
23. K. Wilson, Sex-related difference in drug disposition in man, Clinical Pharmacokinet. 9 (1984), 189-202.